1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Immutep LAG-3 Inhibitor May Have Path Forward

 
• By Joseph Haas

After missing statistical significance in PD-L1+ head-and-neck cancer, Immutep presents data showing eftilagimod with Keytruda can offer efficacy in PD-L1-negative patients.

3d illustration of T cells attacking a cancer cell
Immutep thinks its LAG-3 inhibitor can improve immune response for PD-1 agents

Immutep S.A. thinks it may have identified a niche opportunity for its LAG-3 immunotherapy in head-and-neck cancer, albeit from a small and non-controlled sample of a Phase IIb study that earlier this year yielded uninspiring data. The Australian company and analysts are contending that eftilagimod alfa, in combination with Merck & Co., Inc.’s Keytruda (pembrolizumab), might offer a chemotherapy-sparing regimen that would offer comparable efficacy in a tough-to-treat patient population with better safety and tolerability.

Key Takeaways

  • Hoping to find a path forward after a disappointing Phase II trial in head-and-neck cancer, Immutep finds that its LAG-3 agent combined with Keytruda bests Keytruda monotherapy in PD-L1-negative patients.

At the European Society of Medical Oncology virtual plenary session on 11 July, Immutep reported that eftilagimod produced a 35.5%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Pipeline Watch: Five Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 
• By Dexter Jie Yan

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

More from R&D

Vertex’s Pain Drug Failure Adds To Investor Doubts

 
• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.